As IFPMA members, we believe that the knowledge gained from clinical trials should be used to support the development and use of innovative medicines, vaccines and other therapies, in order to develop the right treatment for the right patient.

We believe that patient populations in clinical trials should be reflective of the epidemiology and demographics of those who would benefit from the therapeutic agent.

To this end, we believe that diversity and inclusion in clinical trials is a matter of both equity and scientific rigor and, as such, that all individuals should have equal opportunity to participate in relevant clinical trials. The biopharmaceutical industry is committed to take affirmative steps to increase clinical trial diversity.